{"url_path":"/sec/grce/10-k/2026/item-2","section_key":"item-2","section_title":"Item 2 **   **Properties**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/1444192/0001140361-26-025662-index.html","accession_number":"0001140361-26-025662","cik":"0001444192","ticker":"GRCE","issuer_name":"Grace Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1444192/0001140361-26-025662-index.html","primary_entity_key":"0001444192","primary_entity_name":"Grace Therapeutics, Inc."},"word_count":20,"has_tables":true,"body_markdown":"**Item 2.**   **Properties**\n\n \n\nOur\nhead office and operations are located at 103 Carnegie Center Suite 300\nPrinceton, New Jersey, 08540."}